trending Market Intelligence /marketintelligence/en/news-insights/trending/ZOUNjXT7gBoa0PPkcUngqA2 content esgSubNav
In This List

Proteon Therapeutics closes $22M preferred stock placement

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Commercial Banking Newsletter June Edition - 2022

Blog

Insight Weekly: US recession outlook; mortgage activity slowdown; climate disclosure push


Proteon Therapeutics closes $22M preferred stock placement

Proteon Therapeutics Inc. closed a private placement of 22,000 of its series A convertible preferred stock, for gross proceeds of $22 million.

The company sold the preferred stock to a syndicate of existing and new investors led by Deerfield Management. Abingworth, Fairmount Funds, Intersouth Partners, Perceptive Advisors, Pharmstandard, RA Capital, Skyline Ventures and TVM Capital also participated in the transaction.

The 22,000 shares of preferred stock are convertible to 22,112,775 common shares, equivalent to an initial conversion price of 99.49 cents apiece.

Proteon Therapeutics plans to use proceeds to complete its ongoing Patency-2 trial and fund continued market access activities. The financing also extends the company's cash runway to the fourth quarter of 2019.

Additionally, Deerfield Management partner Jonathan Leff joined Proteon Therapeutics' board as the preferred stockholders' designee.